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Methotrexate (MTX) was the first reported immunosup-
pressive agent associated with lymphoproliferative disorders 
(LPD) or lymphomas, predominantly in patients being treated 
for rheumatoid arthritis (RA).   Additionally, LPD also 
develop in immunodeficient patients being treated with 
MTX; these LPD were defined as MTX-associated LPD in 
the World Health Organization (WHO) Classification of 
Tumours of Haematopoietic and Lymphoid Tissues 3rd ed. 
(2001).1   However, immunodeficiency-associated LPD also 
develop in patients receiving other immunosuppressive drugs 
such as biologics, tacrolimus, and non-tacrolimus immuno-
suppressants.   Thus, in the WHO classification 4th ed (2008), 
‘MTX-associated LPD’ was changed to ‘Other iatrogenic 
immunodeficiency-associated lymphoproliferative disorders 
(Oii-LPD)’.2
Immunosuppressed patients who are treated using immu-
nosuppressive drugs for an underlying primary disease subse-
quently develop Oii-LPD.   The most common primary dis-
ease is RA, followed by dermatomyositis, psoriasis, psoriatic 
arthritis, systemic lupus erythematosus, and inflammatory 
bowel disease (IBD).   Additionally, according to a published 
paper, the risk factors associated with Oii-LPD onset in Japan 
are the use of methotrexate or tacrolimus and higher age.3
The WHO classification does not clearly indicate the cat-
egory of histological subtypes; however, the framework of 
subtype classification is similar to that of the classification of 
post-transplant LPD, and recent studies have attempted to 
subcategorize Oii-LPD to fit into this unique disease type. 
In this review series, the authors provide an overview of the 
Oii-LPD with respect to their histopathological findings, 
immunophenotype, genetics, clinical behaviors, and clinical 
management.
Most Oii-LPDs are of B-cell lineage such as diffuse large 
B-cell lymphoma-type (35%), classic Hodgkin lymphoma-type 
(25%), or classic Hodgkin lymphoma-like lesions (8%), with 
cases of follicular lymphoma being less common.   Momose 
et al. previously described the clinicopathological and 
genetic features of B-cell type Oii-LPD.
T- or NK-cell type Oii-LPD are rare, and published case 
reports are limited.   To clarify the clinicopathological find-
ings and characteristics of T- or NK-cell type Oii-LPD, Satou 
et al. focused on MTX-associated T-LPD, MTX-associated 
NK/T-LPD, and hepatosplenic T-cell lymphoma in patients 
with IBD.
Epstein-Barr virus (EBV)-positive mucocutaneous ulcers 
were first described as a lymphoproliferative disorder in 2010 
and were classified in the WHO classification revised 4th ed 
(2017) as a specific type of Oii-LPD.4   Ikeda et al. reviewed 
the reported cases of EBV-positive mucocutaneous ulcers, 
focusing on their clinical and pathological aspects as com-
pared with those of other EBV-positive B-cell neoplasms.
The clinical management for Oii-LPD is not established, 
and the prognosis of each histological subtype is unclear, 
excluding the classic Hodgkin lymphoma-type.   Classic 
Hodgkin lymphoma-type does not exhibit remission with 
MTX discontinuation alone and requires additional chemother-
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apy.5   Tokuhira et al. summarized the prognosis of each his-
tological subtype and their clinical management.
A significant proportion of patients with Oii-LPD demon-
strate partial or complete regression in response to the with-
drawal of immunosuppressive drugs.   Although the reason is 
unclear, recent studies suggest that the early recovery of the 
absolute lymphocyte count after withdrawal of MTX is asso-
ciated with the spontaneous regression of MTX-associated 
LPD.   Saito et al. summarized the immune response in 
patients with Oii-LPD, and discussed the relationship 
between prognosis and absolute lymphocyte count (this 
review article will be published in the next issue).
All reviews reflect the past to present knowledge of Oii-
LPD, and are expected to help clinicians, pathologists, and 
researchers.
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